Please login to the form below

Not currently logged in
Email:
Password:

pulmonary artery hypertension

This page shows the latest pulmonary artery hypertension news and features for those working in and with pharma, biotech and healthcare.

EU nod for Actelion's skin cancer drug Ledaga

EU nod for Actelion's skin cancer drug Ledaga

The green light is a minor boost to Actelion's efforts to expand its specialty drugs business beyond its core portfolio of treatments for pulmonary artery hypertension, which still account for

Latest news

  • J&J agrees $30bn deal to acquire Actelion J&J agrees $30bn deal to acquire Actelion

    Meanwhile, J&J claims the company's marketed products including its trio of pulmonary artery hypertension (PAH) drugs, including Tracleer (bosentan) - now facing generic competition - as well as follow-up drugs ... ACT-132577, an Actelion candidate for

  • Actelion reports late-stage trial failure as J&J talks continue Actelion reports late-stage trial failure as J&J talks continue

    MAESTRO involved 266 patients with pulmonary artery hypertension (PAH) caused by Eisenmenger syndrome, an umbrella term for congenital cardiac defects that lead to left-to-right shunts - reversal of blood flow ... from the right side of the circulation

  • J&J back in frame to buy Actelion after Sanofi talks break down J&J back in frame to buy Actelion after Sanofi talks break down

    Actelion has been through a difficult patch after losing patent protection for pulmonary artery hypertension (PAH) blockbuster Tracleer (bosentan), but is on the up with strong growth for follow-up PAH

  • J&J abandons talks with Actelion as another suitor circles J&J abandons talks with Actelion as another suitor circles

    After a challenging couple of years following the loss of patent protection for pulmonary artery hypertension (PAH) blockbuster Tracleer (bosentan), Actelion is now riding high on the back of strong growth

  • Resurgent Actelion catches J&J's eye Resurgent Actelion catches J&J's eye

    Strong early sales of Actelion's pulmonary artery hypertension drug Uptravi have drawn the attention of Johnson &Johnson (J&J). ... place. Buying Actelion would give J&J a portfolio of drugs for PAH, a disorder that causes the artery walls in the lungs

More from news
Approximately 2 fully matching, plus 8 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Wisepress

Wisepress is a medical bookseller promoting and selling books worldwide, both online and via the 200 European medical conferences that...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics